7.76 (1H, t, J = 8.2 Hz, ArH) 8. 40 (1H, d, J = 7.3 ArH), 8.81 (1H, d, J = 6 .0 Hz, ArH), 9.04 (2H, d, J = 5.3 Hz, ArH); δ C (75.5 MHz, CDCl 3 ) 211. 0, 170.5, 168.7, 166.7, 159.4, 158.9, 157.5. 140.5, 134.6, 129.4, 125.2, 124.2, 121.6, 118.8, 116.0, 37.0, 28.4 (3C) 92, 170.87, 168.46, 158.93, 140.58, 133.22, 130.47, 128.07. 124.03, 122.97, 121.61, 114.35, 110.29, 100.92, 45.91, 28.35 (3C), 22.72, 12.28 . LC-MS-EI 411.5 (M+H + ). 24, 168.48, 141.16, 140.40, 139.98, 133.44, 130.03, 128.55 (2), 127.74, 126.72, 123.74, 123.01, 121.60, 121.33, 119.42 (2), 118.49, 110.17, 107.83, 53.57, 36.91, 28.34 (3) .
tert-Butyl-N-[[5-[1-[(4-pyrazol-1-ylphenyl)methyl]indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]carbamate (22

LC-MS-EI 472.2 (M+H + )
. 4, 168.4, 148.2, 147.7, 140.4, 129.9, 129.1, 127.6, 123.7, 123.2, 121.6, 121.1, 110.3, 108.4, 108.0, 101.3, 54.2, 37.0, 28.4 
. LC-MS-EI 450.4 (M+H + ).
General Method for the Mitsunobu Synthesis of the N2-Benzyl-Substituted
Oxadiazoles: To a solution of 3-[3-tert-Butoxycarbonylaminomethyl-1,2,4-oxadiazol-5-yl]indazole (0.25 g, 0.79 mmol), under nitrogen, in toluene (10 mL), benzyl alcohol (0.87 mmol), tributylphosphine (0.26 g, 0.31 mL, 1.26 mmol), and TMAD (0.22 g, 1.26 mmol) were added successively. The resulting clear-yellow solution was allowed to stir overnight at room temperature. The solution was then extracted with water, 1 N HCl, 1 N sodium hydroxide (aq), and brine. The combined aqueous phases were washed with dichloromethane and the combined organic phases dried over magnesium sulfate. The solvent was removed in vacuo. Unless otherwise stated, the crude compounds were purified using column chromatography (4:1 cyclohexane/ethyl acetate) 170.0, 169.0, 158.2, 149.5, 138.7, 129.1, 128.5, 126.9, 124.0, 121.3, 121.1, 121.0, 119.2, 80.8, 54.4, 47.8 , 37.2, 23 167.31, 155.58, 147.21, 139.02, 126.93, 126.93, 126.04, 125.50, 124.64, 122.35, 119.99, 118.86, 118.18, 78.34, 53.97, 36.01, 29.82, 28.10; FAB-MS: Requires 448.14192, Found 448.14225 (M+Na + ) .
tert-Butyl((5-(2-(2-(1H-imidazol-1-yl)ethyl)-2H-indazol-3-yl)-1,2,4-oxadiazol-3-yl)methyl)carbamate (17
General Method for the Deprotection of the Boc-Protected Oxadiazoles:
The bocprotected oxadiazoles (0.03 g-0.25 g) were dissolved in trifluoroacetic acid (1.9 mL, 95%), and then triisopropylsilane (0.05 mL, 2.5%) and water (0.05 mL, 2.5%) were added. The solution was allowed to stir for 18 h at room temperature. Ice-cold diisopropyl ether or diethyl ether was added until a white precipitate started to form. The white precipitate was then filtered off and allowed to dry. The amines were generally used directly in the acylation step.
[ 39, 165.70, 140.75, 135.93, 129.17, 127.83, 124.03, 122.16, 121.73, 120.60, 120.17, 113.58, 110.61, 48.85, 47.96, 34.18 ; LC-MS-EI: 310.4 (M+H + ).
[ 167.65, 165.21, 158.61, 147.37, 136.04, 127.36, 126.14, 122.52, 120.26, 118.91, 118.29, 113.57, 52.78, 47.90, 34.09 11, 165.94, 159.42, 158.10, 156.59, 139.86, 132.85, 129.55, 126.25, 125.31, 123.34, 120.92, 119.88, 115.85, 34.25 170.68, 165.64, 155.32, 149.31, 141.02, 137.36, 127.77, 127.23, 128.64, 123.93, 123.13, 122.08, 120.45, 110.98 76, 170.53, 165.71, 159.42, 140.60, 128.98, 127.99, 124.11, 121.98, 120.58, 111.25, 101.16, 45.00, 34.21, 11.67 71, 165.41, 147.40, 146.99, 140.15, 129.70, 128.42, 127.71, 123.93, 122.11, 121.44, 120.52, 111.38, 108.29, 108.22, 101.09, 52.72, 34. 167.6, 148.6, 137.6, 133.6, 131.9, 129.2, 128.6, 127.7, 127.4, 126.2, 123.0, 120.6, 120.1, 119.4, 118.3, 53.3, 47.1, 35.7 155.52, 149.36, 149.36, 140.93, 137.20, 133.66, 131.49, 129.10, 128.35, 128.35, 127.59, 127.28, 127.28, 123.73, 123.02, 121.88, 120.45, 111.40, 54.51, 35.23 168.55, 166.50, 147.24, 138.98, 138.98, 133.68, 131.51, 128.36, 128.36, 127.29, 126.89, 126.89, 125.98, 125.58, 124.59, 122.36, 119.96, 118.83, 118.21, 114.75, 53.96, 35.14, 29.85 76, 170.50, 169.98, 168.92, 166.48, 159.49, 140.50, 133.66, 131.50, 129.44, 128.35, 127.28, 123.92, 121.90, 120.57, 111.08, 101.12, 44.90, 35.24, . 170.0, 168.9, 164.7, 155.9, 152.0. 141.5, 140.8, 137.3, 129.2, 128.4, 127.4. 125.3, 123.7, 121.5, 120.3, 119.6,, 199.3, 110.5, 107.9, 61.8, 60.5, 56.0, 49.8, 45 162.88, 152.56, 150.68, 140.18, 136.80, 134.50, 129.98, 129.80, 128.61, 127.61, 127.26, 126.78, 124.21, 121.66, 120.71, 120.45, 120.04, 119.90, 113.06, 101.62, 48.89, 45.11, 40.29 . LC-MS-EI 453.5 (M+H + ). 170.07, 156.71, 142.66, 138.44, 132.19, 131.54, 128.92, 128.85, 128.85, 128.42, 126.58, 126.58, 124.82, 123.45, 122.13, 120.86, 110.71, 51.14, 47.56, 36.71, 35.70, 35.82 04, 168.82, 167.80, 165.54, 152.95, 152.55, 147.41, 146.74, 140.81, 129.24, 127.40, 124.06, 123.78, 121.53, 121.03, 120.31, 119.33, 115.25, 110.49, 60.72, 55.79, 49.82, 45.49, 35.25 14, 168.64, 164.90, 148.31, 140.82, 135.80, 130.68, 129.18, 127.41, 126.42, 126.42, 124.14, 124.14, 123.67, 123.67, 121.51, 120.29, 119.78, 118.29, 110.54, 49.83, 45.47, 35.29 23, 167.21, 165.53, 147.33, 137.32, 136.39, 132.40, 129.23, 128.49, 128.27, 127.08, 125.70, 122.26, 119.96, 119.33, 119.22, 118.22, 53.27, 45.59, 35.14 51, 167.16, 166.62, 166.01, 147.34, 129.17, 129.17, 129.17, 128.30, 127.08, 125.87, 125.69, 122.25, 119.98, 119.34, 118.22, 113.57, 99.26, 55.31, 53.27, 45.60, 35. 
N-[[5-[1-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]-2,3,4-trimethoxy-benzamide (38
4-tert-Butyl-N-[[5-[1-(2-imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]benzamide (40
. 95, 168.13, 167.26, 164.96, 151.20, 148.34, 147.35, 137.33, 135.81, 130.68, 128.25, 127.08, 126.41, 125.70, 124.15, 122.28, 119.96, 119.79, 119.23, 118.23, 53.29, 45.60, 35.20 . 3, 165.0, 150.5, 147.4, 142.5, 137.4, 132.8, 131.7, 128.3, 127.1, 126.2, 125.7, 124.5, 122.3, 120.0, 199.3, 119.2, 118.3, 113.6, 53.3, 45.6 82, 167.82, 167.79,148.52, 138.49, 133.56, 132.62, 128.92, 128.49, 128.11, 127.67, 126.15, 124.34, 122.94, 120.53, 120.06, 119.37, 118.32, 53.24, 46.96, 35.70, 29.70, 21.33; ESI-MS: Requires 450.16635, Found 450.16544 (M+Na + ) . 92, 168.44, 167.18, 166.64, 165.24, 157.23, 147.33, 136.73, 132.78, 130.67, 127.17, 122.33, 121.83, 120.53, 120.02, 119.30, 118.21, 115.97, 112.13, 55.92, 53.08, 46.52, 35.37; ESI-MS: Requires 444.17841, Found 444.17988 (M+H + ). 42, 168.34, 167.20, 166.27, 159.17, 147.34, 135.07, 129.53, 128.30, 125.71, 122.27, 119.99, 119.52, 119.25, 118.24, 117.44, 116.45, 115.16, 112.39, 55.23, 53.30, 45.61, 35.11; ESI-MS: Requires 444.17841, Found 444.17863 (M+H + ). 169.78, 167.36, 146.20, 138.35, 135.45, 132.33, 132.10, 130.57, 129.16, 127.52, 126.42, 125.87, 124.97, 124.66, 123.61, 121.50, 120.48, 110.47, 49.32 . LC-MS-EI 464.5 (M+H + ). -1-ylethyl) 167.46, 140.78, 139.81, 137.29, 137.01, 128.91, 128.39, 127.41, 123.59, 121.46, 120.39, 119.30, 110.48, 49.82, 45.44, 37.94 169.8, 167.3, 151.8, 148.3, 140.8, 137.3, 131.8, 129.0, 128.4, 127.4, 123.5, 121.4, 120.3, 119.3, 113.5, 110.8, 110.4, 109.3, 55.5, 49.9, 45.5, 37.8, 24.9 169.78, 167.36, 146.20, 138.35, 135.45, 132.33, 132.10, 130.57, 129.16, 127.52, 126.42, 125.87, 124.97, 124.66, 123.61, 121.50, 120.48, 110.47, 49.32, 46.50, 37.40, 19.83 04, 168.65, 143.45, 142.48, 137.73, 131.80, 131.45, 131.45, 131.32, 130.69, 130.51, 130.20, 129.15, 127.84, 124.96, 123.87, 123.42, 122.29, 110.74, 50.53, 48.19, 39.18 ; ESI-MS: Requires 518.12222, Found 518.12347 (M+H + ). 167.22, 155.18, 150.96, 145.25, 140.78, 137.44, 129.07, 127.49, 126.38, 125.57, 125.26, 125.26, 124.28, 124.28, 123.60, 121.52, 110.49, 49.64, 47.50, 37.68, 34.26, 31.02, 31.02, 30.351; ESI-MS: Requires 506.19743, Found 506.19612 (M+H + ) . 072, 167.00, 147.29, 140.55, 137.36, 132.26, 128.92, 128.92, 128.31, 127.11, 126.47, 126.47, 125.73, 122.24, 119.97, 119.42, 118.98, 118.22, 53.25, 45.57, 37.81 168.62, 166.99, 166.71, 149.64, 147.29, 142.74, 137.36, 133.80, 128.21, 127.71, 127.04, 125.67, 122.22, 119.97, 119.46, 118.87, 118.05, 53.21, 45.65, 37.63, 23.85 . LC-MS-EI 507.4 (M+H + ).
N-[[5-[2-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]-2,3-dimethoxybenzamide (50
N-[[5-[2-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]-3-(trifluoromethoxy)benzamide (51
LC-MS-EI 498.4 (M+H + ).
N-[[5-[2-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]-3-methyl-4-nitro-benzamide (52
N-[[5-[2-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]-2-methoxybenzamide (55
N-[[5-[2-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]-3-methoxybenzamide (56
Sulfonamide analogues N-((5-(1-(2-(1H-Imidazol-1-yl)ethyl)-1H-indazol-3-yl)-1,2,4-oxadiazol-3-yl)methyl)-2-methylbenzenesulfonamide (60
4-Chloro-N-[[5-[1-(2-imidazol
4-tert-Butyl-N-[[5-[1-(2-imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]benzenesulfonamide (62
N-((5-(2-(2-(1H-Imidazol-1-yl)ethyl)-2H-indazol-3-yl)-1,2,4-oxadiazol-3-yl)methyl)benzenesulfonamide (63
In Vitro Preparation of Rat Forebrain Synaptosomes and Homogenates:
Experiments were performed using forebrain from Male Wistar rats weighing 175g to 250 g. All efforts were made to reduce the number of animals used, and all experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act, 1986 and the European Community Council Directive of 24 November 1986 (86/609/EEC). After killing of animals gassing discontinued. Exactly 11 min later, three to four slices were removed and transferred to microfuge tubes containing TCA (as above) for measurement of ATP and protein.
Measurement of ATP and Protein:
Briefly, individual slices were ultrasonicated and the resulting homogenates centrifuged (10,000 rpm for 5 mins at 4 °C). the resulting pellet was resuspended in 5mL 0.1 M KOH by ultrasonication and warmed with gentle agitation at 37°C for 30 min. Concentrations of ATP were measured by mixing with Luciferase reagent (ATPLite from Perkin-Elmer) and measuring subsequent luminescence. Protein concentrations were measured using BCA protein assay (Pierce) with bovine serum albumin as standard. ATP concentrations were expressed as nmol/mg protein and % neuroprotection was calculated by comparison with 1 µM tetrodotoxin.
Na v Isoform Screening: Patch-clamp experiments against hNa v 1.1 to hNa v 1.8/β3 were performed by Chantest Inc., Cleveland, OH. Briefly, test compounds were evaluated at room temperature using the PatchXpress 7000A (Molecular Devices), an automatic parallel patchclamp system. Compounds were evaluated at 0.1, 0.3, 1, 3, 10, 30 and 100 µM Concentration, being tested in two to four cells. The duration of each exposure was 5 min. Use-dependence of inhibition on hNa v 1.1 and hNa v 1.8/β3 was determined using a double pulse protocol. A holding potential of -80 mV and prepulse potential of -120 mV were followed by pulse 1-0 mV for 200 ms. An interpulse potential of -80 mV was then applied for 200 ms, followed by a second pulse of 0 mV for 20 ms. The pulse pattern was repeated at 10 s intervals (0.1 Hz), and peak current amplitudes at both test pulses were measured. Percentage use-dependent inhibition (I) was calculated from the equation I = (1 -P2T/P1T) × P1C/P2C × 100, where P1 and P2 refer to the current amplitudes produced by the first and second pulses, respectively, RatHepaticMicrosomalStability. Briefly, compounds (1µM) were incubated (n=2) with pooled rat liver microsomes (0.25mg protein/ml) at 37 o C for 0 and 40 min before termination of reactions and extraction of compound with acetonitrile containing carbamazepine as analytical internal standard. Samples were centrifuged and the resultant supernatant analysed for disappearance of parent compound by mass spectrometry (LC-MS/MS). The instrument responses (peak heights) of the incubated samples were referenced to the zero time-point samples in order to determine the percentage turnover of compound. Induction of chronic-relapsing EAE: Mice received subcutaneous injections in the flank of 1mg freeze-dried mouse spinal cord homogenate (SCH) in Freund's adjuvant supplemented with 60µg Mycobacterium tuberculosis H37Ra and M. butyricum on day 0 and 7, as previously described (Baker et al. 1990) . Following the development of the initial paralytic disease and subsequent remission a relapse was induced by a further injection of SCH in Freunds adjuvant on day 27 (O'Neill et al. 1992b ). Animals were monitored and weighed daily to assess the development of relapsing-remitting paralysis. Clinical scores were graded as 0 = Normal; 1 = Limp tail, 2 = impaired righting reflex, 3 = hindlimb paralysis and 4 = complete hindlimb paralysis, 5 = moribund/death. Signs of reduced severity were scored at 0.5 less than the indicated grade as described previously (Baker et al. 1990 , O'Neill et al. 1992a . A clinical relapse was associated with an increase in neurological disease and weight loss (>5%) as described previously (Baker et al. 1990) . RotaRod: Motor control and coordination was assessed on an accelerating (4-40 rpm, accelerating at 6rpm/25s) RotaRod (ENV-575M. Med Associates Inc, St. Albans, VT, USA). Activity was assessed during the remission phases of the disease, over a maximum 5 minute observation period. The trial was terminated when the mouse either fell from the RotaRod spindle or if the mouse failed to tolerate the revolving drum shown by holding onto the RotaRod spindle rod for two consecutive turns. Following the develop of the initial acute phase paralytic attack and remission animals were randomized within cages, based on clinical score, to receive either an intra-peritoneal (i.p.) injection of either vehicle or CFM6104. This was administered just before the anticipated onset of relapsing disease from day 33 post-induction (p.i.) onwards.
Neurofilament ELISA. An enzyme linked immunosorbent assay for heavy chain neurofilament was performed as previously described (Jackson et al. 2005) . Briefly whole spinal cord samples were homogenized with a glass homogenizer, centrifuged (20,000g) and the supernatant was collected for analysis. A 96 well plate was coated overnight at 4°C with capture antibody (SMI-35 anti-neurofilament H. Covance Inc. Cambridge Bioscience, Cambridge, UK). Following one wash in wash buffer (11 mM barbital, 63 mM sodium barbital, 1.2 mM EDTA, Sigma), non-specific binding was blocked by incubation with 5% bovine serum albumin in wash buffer for 1 hour at room temperature. Following a wash step, samples and standards (Bovine neurofilament heavy chain. Sigma, Poole, UK) were diluted in wash buffer with 1% bovine serum albumin and incubated on the plate for 2 hours at room temperature. Following 3 wash steps, the horseradish peroxidase conjugated, detector antibody was applied (rabbit anti-NF200, Sigma) and incubated for a further hour at room temperature. Following a final 3 washes, tetramethylbenzidine substrate was applied and colour production measured on a Synergy HT plate reader at 405nm with a reference at 720nm 2 .
Statistical analysis:
The data is presented as mean ± standard error of the mean (SEM). Differences in clinical scores between groups were assessed using non-parametric, Mann Whitney U statistics. The parametric data was assessed using t tests, incorporating tests for equality of variance using Sigmastat software (Systat Software, Inc., San Jose, USA).
